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Aims: Racemic ibuprofen is widely used for the treatment of preterm neonates
with patent ductus arteriosus. Currently used bodyweight-based dosing guidelines
are based on total ibuprofen, while only the S-enantiomer of ibuprofen is pharma-
cologically active. We aimed to optimize ibuprofen dosing for preterm neonates
of different ages based on an enantiomer-specific population pharmacokinetic
model.
Methods: We prospectively collected 210 plasma samples of 67 preterm neonates
treated with ibuprofen for patent ductus arteriosus (median gestational age
[GA] 26 [range 24–30] weeks, median body weight 0.83 [0.45–1.59] kg, median post-
natal age [PNA] 3 [1–12] days), and developed a population pharmacokinetic model
for S- and R-ibuprofen.
Results: We found that S-ibuprofen clearance (CLS, 3.98 mL/h [relative standard
error {RSE} 8%]) increases with PNA and GA, with exponents of 2.25 (RSE 6%) and
5.81 (RSE 15%), respectively. Additionally, a 3.11-fold higher CLS was estimated for
preterm neonates born small for GA (RSE 34%). Clearance of R-ibuprofen was found
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to be high compared to CLS (18 mL/h [RSE 24%]), resulting in a low contribution of
R-ibuprofen to total ibuprofen exposure. Current body weight was identified as
covariate on both volume of distribution of S-ibuprofen and R-ibuprofen.
Conclusion: S-ibuprofen clearance shows important maturation, especially with PNA,
resulting in an up to 3-fold increase in CLS during a 3-day treatment regimen. This
rapid increase in clearance needs to be incorporated in dosing guidelines by adjusting
the dose for every day after birth to achieve equal ibuprofen exposure.
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1 | INTRODUCTION
Patent ductus arteriosus (PDA) is diagnosed when spontaneous clo-
sure of the ductus arteriosus does not occur. Preterm neonates with
the lowest gestational age (GA) are at highest risk of PDA.1 Numerous
poor outcomes are associated with PDA, but currently there is no
consensus on if, how and when to treat PDA in preterm neonates and
PDA treatment policies vary widely.2
If one decides to treat the PDA, ibuprofen is currently considered
as the drug of choice. Ibuprofen showed lower risks for side-effects
and a potential decreased risk for necrotising enterocolitis compared
to indomethacin, whereas the role of acetaminophen for PDA still
remains to be determined.3–6 In addition, the reduction in clearance
of the renally excreted antibiotic vancomycin was lower when ibupro-
fen instead of indomethacin was administered, suggesting less
nephrotoxicity.4
Ibuprofen is available as a racemic mixture of R- and S-ibuprofen,
with S-ibuprofen being the pharmacologically active drug.7 A 3-day
dosing regimen starting with a loading dose of 10 mg/kg followed by
5 mg/kg/day for 2 days is registered for intravenous ibuprofen.8
Throughout the years the registered dosing regimen has undergone
many off-label adaptations, such as an increase in dose with PNA on
the day of treatment initiation, as suggested by Hirt et al.9 These
authors also defined a minimal target exposure to total ibuprofen of
an area under the curve 24 hours after the first dose (AUC24) of
600 mg h/L, at which PDA closure was observed in 91% of their
population.9
Enantiomer specific pharmacokinetic (PK) studies were performed
by Gregoire et al., who reported substantial differences between the
clearance of S-ibuprofen (CLS) and R-ibuprofen (CLR).
10,11 A simula-
tion study was recently performed by Flint et al. to translate these
findings into a dosing regimen.12 However, due to the relatively nar-
row range in PNA (0–8 days) of the population examined by Gregoire
et al., further investigation of the maturation of enantiomer specific
ibuprofen PK is desirable before implementation of the proposed dos-
ing regimen.11,12
Current ibuprofen dosing advices do not recognize the
enantiomer-specific PK and activity, nor do they take into account the
exact influence of covariates such as PNA and GA. In our study, we
aim to gain more insight into the enantiomer specific PK of ibuprofen
in preterm neonates with PDA. By analysing data from different cen-
tres, we account for the varying treatment approaches with respect to
PNA at treatment initiation, dosages and treatment duration used in
the Netherlands. The overall aim of this study is to develop a popula-
tion PK model on which to perform a covariate analysis to identify
how patient characteristics affect the enantiomer specific PK. Finally,
we will perform simulations to explore the exposure in different
patient groups, which can guide clinicians to individualize dosing
regimens.
What is already known about this subject
• Ibuprofen is often used for the treatment of patent
ductus arteriosus in preterm neonates.
• Ibuprofen is administered as a racemic mixture of S- and
R-ibuprofen, while only S-ibuprofen is pharmacologically
active.
• Dosing strategies vary widely across neonatal intensive
care units, but have in common that they are based on
racemic pharmacokinetic and pharmacodynamic studies.
What this study adds
• Enantiomer specific pharmacokinetic parameters were
characterized in 67 preterm neonates and indicate that
ibuprofen doses should be based on weight and postnatal
age in preterm neonates.
• Next to characterization of the maturation of the clear-
ance of both S- and R-ibuprofen over a wide range of
postnatal age, an unexpectedly high clearance in small for
gestational age neonates was found.
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2 | METHODS
2.1 | Study
This study was part of the Drug dosage Improvement in Neonates
(DINO) study (NCT 02421068), a prospective study that used oppor-
tunistic blood sampling to evaluate and improve current dosage guide-
lines of drugs in preterm neonates. Next to ibuprofen, 8 other drugs
were studied in preterm neonates born before 32 weeks of gestation
and admitted to 1 of 4 collaborating neonatal intensive care units
(NICUs). Patients were treated with intravenous or gastro-enteral ibu-
profen (Pedea, Recordati Ireland Ltd.) according the standard of care
of the participating NICU. Each blood sample was <1% of the total
blood volume per day, and the maximal blood sample volume did not
exceed 3% of the total blood volume per 4 weeks. The local ethics
review board approved the protocol and both oral and written
informed consent from parents/legal guardians were obtained prior to
study initiation (MEC-2014-067). Blood samples were centrifuged
and plasma was isolated and frozen (−80C) until analysis.
2.2 | Bioanalytical analysis
S- and R-ibuprofen were quantified based on a validated ultra-
performance liquid chromatography UV analysis method, developed
by the OECD GLP (Good Laboratory Practice) compliant Department
of Pharmacology, Toxicology and Biochemistry of the Faculty of Vet-
erinary Medicine, Ghent University.13 The lower limit of quantification
was set at 1 μg/mL for both enantiomers, the limit of detection was
0.0359 and 0.225 μg/mL for S- and R-ibuprofen, respectively. Intra-
and interassay accuracies ranged from −4.3 to 5.8% and 2.5 to 4.4%,
respectively, for S-ibuprofen, and from −9.4 to 6.5% and −2.3 to 2.8%
for R-ibuprofen. Intra- and interassay imprecision did not exceed
10.1% for S- or R-ibuprofen.
2.3 | Population PK analysis
2.3.1 | Software
NONMEM version 7.3 (ICON Development Solutions, Ellicott City,
MD, USA) was used for model development, supported by Perl-
speaks-NONMEM version 4.7.0. R version 3.5.1 was used in Rstudio
version 1.1.463 to build the dataset and visualize the data and model
output. R version 3.1.2 was loaded to perform a normalized prediction
distribution error (NPDE) analysis.14
2.3.2 | PK model development
First, we developed a model for S-ibuprofen using the first-order con-
ditional estimation with interaction method. As dose, half of the
administered dose of the racemic mixture of ibuprofen was assumed
to be S-ibuprofen.15 Model-development was based on comparison of
objective function value (OFV) for nested models, and numerical and
graphical model performance (relative standard error [RSE] < 50% and
no trends in conditional weighted residuals [CWRES] vs time after
dose and observed concentrations). A stepwise covariate analysis-
based covariate analysis was performed manually, to prevent addition
of correlated covariates (e.g. PNA and postmenstrual age [PMA]).
Covariates to test were selected by visual examination of plots of
interindividual variability (IIV) estimates vs all available covariates.
Potential covariate relationships were tested and added based on
significant improvement in OFV and improvement of goodness-of-
fit plots, if not correlated to already included covariates. Signifi-
cance levels of P ≤ .01 and P ≤ .001 (6.6 and 10.8 points in OFV,
respectively) were used for forward inclusion and backward exclu-
sion of the covariates, respectively. Body weight was not mea-
sured daily, and therefore interpolated linearly for days on which
no measurements were available. Linear interpolation was used in
a similar fashion for bilirubin and albumin when data were avail-
able. For individuals lacking bilirubin or albumin data (n = 24 and
52, respectively), the median observed in our population was
imputed.
For the development of the S- and R-enantiomer model, R-
ibuprofen concentrations were added to the S-ibuprofen model,
thereby allowing description of the separate PK of both enantiomers
simultaneously. At this point, the M3 method was applied to include
all data below lower limit of quantification (2 and 69% of S- and R-
enantiomer, respectively), thereby changing the estimation method to
Laplacian with interaction.16 A potential inversion of R- to S-ibuprofen
was estimated as a second rate constant from the R-ibuprofen com-
partment to the S-ibuprofen compartment as described before.11 The
effect of PNA on CLR was tested based on the results of Gregoire
et al.11
2.3.3 | Model evaluation
The performance of key models was evaluated by NPDE and boot-
strap analyses, based on 1000 simulations of the data.17 A prediction-
corrected visual predictive check was performed to assess the perfor-
mance of the M3 method.18
2.3.4 | Evaluation and optimization of the dosing
regimen
The final model was used to evaluate ibuprofen exposure for 2 different
dosing regimens, intravenous dosing according to the label
(10-5-5 mg/kg/day) and dosing according to the currently advised dos-
ing regimen suggested by Hirt et al.9 A set of 18 hypothetic preterm
neonates were created, with their PNA and GA set manually to repre-
sent the observed variation in these covariates in the study population.
Nine were appropriate for GA (AGA) and 9 small for GA (SGA). AGA
birth weights were imputed based on the median intrauterine weight,
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and SGA birth weight was based on the 10th percentile of the intrauter-
ine growth curves.19 In both the AGA and SGA group, simulations were
performed for ibuprofen treatment starting at a PNA of 1, 3 and 7 days
for subjects with a GA of 25, 27 and 29 weeks. Body weight was
assumed to remain unchanged during the simulation period, and 1000
simulations were run per subject and dosing regimen.
A heat map was made to evaluate the variability in exposure to
total ibuprofen of preterm neonates across the range of PNA and GA
of the study populations. For this purpose, a population of a total of
33 subjects were created, with a PNA at treatment initiation ranging
from 1 to 8 days, and a GA ranging from 24 to 28 weeks. Birth weight
of these subjects was imputed based on intrauterine growth curves.19
The median weights of male and female foetuses at their set GA were
averaged to represent 1 birth weight.19 Body weight was assumed to
remain equal to birthweight during the simulation period. Each subject
was simulated 1000 times. To prevent extrapolation outside the
observed combinations of GA and PNA, combinations missing in our
dataset were removed from this plot.
Based on observed trends in the concentration–time profiles and
heat maps the currently used dosing regimens were optimized, aiming
for similar exposure across the PNA and GA ranges. During the simu-
lations, a more frequent dose adjustment for increasing PNA was also
examined.
3 | RESULTS
3.1 | Patients and samples
A total of 210 plasma samples of 67 neonates were collected in which
the concentrations of S- and R-ibuprofen were measured. Four
patients, with 1 sample each, who received ibuprofen gastroenterally
TABLE 1 Patient characteristics (median (range)) and dosing information of the population, up to the last available sample. For time-changing
characteristics the median of the individual median is presented. Ibuprofen doses are calculated based on absolute dose administered and
(interpolated) current weight. Loading and maintenance doses were based on a 3-day regimen and identified by number of dose
Appropriate for gestational age Small for gestational age Total population
Patient characteristics
Preterm infants (n) 60 7 67
Sex (male/female) 32/28 3/4 35/32
Gestational age (wk) 26.1 (24.0–30.1) 26.7 (24.6–28.9) 26.1 (24.0–30.1)
Birth weight (kg) 0.91 (0.59–1.45) 0.67 (0.47–0.95) 0.87 (0.47–1.45)
Current weight (kg) 0.85 (0.53–1.59) 0.74 (0.45–1.04) 0.83 (0.45–1.59)
Part of twin (n) 30 3 33
Postnatal age at treatment initiation (d) 3 (1–8) 4 (2–12) 3 (1–12)
Bilirubin (μmol/L) [number of patients] 97.4 (42.5–177.3) [37] 75.5 (47.7–104.3) [6] 94.9 (42.5–177.3) [43]
Albumin (g/L) [number of patients] 28.9 (25.0–36.5) [14] 26.6 [1] 28.7 (25.0–36.5) [15]
Coadministration of fluconazole (n) 17 2 19
Ibuprofen dosing
Duration of ibuprofen treatment (d) 3 (0–15) 2 (1–4) 3 (0–15)
Infusion duration (min) 15 (3–30) 15 (0–30) 15 (0–30)
Entire treatment period
Dose of ibuprofen (mg/kg) 9.6 (4.6–22.7) 8.1 (4.5–20.4) 9.5 (4.5–22.7)
First treatment cycle
Loading dose of ibuprofen (mg/kg) 11 (5–23) 10 (7–20) 11 (5–23)
Maintenance dose of ibuprofen (mg/kg) 6 (5–15) 5 (4–9) 6 (4–15)
Second treatment cycle
Loading dose of ibuprofen (mg/kg), n 18 (5–20) [17] 19 (7–20) [3] 18 (5–20) [20]
Maintenance dose of ibuprofen (mg/kg), n 9 (5–19) [11] 9 (5–19) [11]
Third treatment cycle
Loading dose of ibuprofen (mg/kg), n 14 (8–20) [4] 14 (8–20) [4]
Maintenance dose of ibuprofen (mg/kg), n 9 (9–10) [3] 9 (9–10) [3]
Samples
Time after last dose (h) 15.9 (0–112.4) 15.3 (0.5–22.1) 15.8 (0–112.4)
Observed concentrations S-ibuprofen (mg/L) 20.61 (0.08–84.17) 9.22 (0.91–31.78) 20.02 (0.08–84.17)
Observed concentrations R-ibuprofen (mg/L) 0 (0–24.73) 0 (0–9.45) 0 (0–24.73)
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were excluded a priori since these data were regarded as too sparse to
describe the absorption and bioavailability upon oral administration.
Patient characteristics are presented in Table 1.
3.2 | Population PK model of S-ibuprofen
Plasma concentrations of S-ibuprofen were best described by a
1-compartment model with IIV on clearance and volume of distribu-
tion of S-ibuprofen (CLS and VS, respectively) and a proportional error
to describe the residual variability. Observed concentrations of S-
ibuprofen plotted against time after dose did not suggest any
nonlinear PK of S-ibuprofen (Figure S1) within the concentration
range observed in this study. Current weight (WT), birth weight, PNA,
PMA, GA, sex, being SGA (birth weight lower than the 10th percentile
of their respective gestational growth curves19), bilirubin and albumin
plasma concentrations, and being born from a multiple pregnancy
were tested as covariates (Figure S2).
Both PNA and GA were found most predictive for CLS (P < .001
[−108 points in OFV] and P < .001 [−18 points in OFV], respectively),
and were implemented in the model. Being SGA was identified as an
additional significant covariate on CLS, with an estimated 3.11-fold
increase in CLS compared to AGA preterm neonates (P < .001 [−21
points in OFV]). For Vs, both WT and sex were significant covariates,
TABLE 2 Parameter estimates of the final models and their corresponding bootstrap estimates
S-ibuprofen R- and S-ibuprofen
Final model estimates (RSE %)
[shrinkage %]
Bootstrap estimate
(95% CI)
Final model estimates (RSE %)
[shrinkage %]
Bootstrap estimate
(95% CI)
S-ibuprofen parameters
CLS,ind = CLS,pop
* (PNAind/6 days)
ΘPNA,S * ΘSGA * (GAind/26 weeks)ΘGA
CLS,pop (mL/h) 3.96 (9) 4.20 (3.37–5.28) 3.98 (8) 4.27 (3.39–5.23)
ΘPNA,S 2.41 (9) 2.21 (1.32–2.67) 2.25 (6) 1.98 (1.27–2.63)
ΘSGA 3.42 (27) 3.00 (2.02–3.39) 3.11 (34) 3.02 (1.94–4.56)
ΘGA 5.98 (15) 5.86 (3.82–8.22) 5.81 (15) 5.57 (3.43–8.13)
VS,ind = VS,pop
* (WTind/860 g)
ΘWT
VS,pop (mL) 248 (8%) 239 (192–293) 231 (5) 220 (187–259)
ΘWT 0.645 (38%) 0.633 (0.123–1.22) 0.60 (0.22–1.21)
Interindividual variability (IIV)
IIV on CLS (%) 42.9 (14%) [16] 42.9 (29.4–61.4) 46.7 (21) [16] 40.9 (28.8–60.2)
IIV on VS (%) 31.2 (32%) [33] 30.2 (11.3–47.6) 25.9 (19) [33] 23.1 (9.8–41.2)
Covariance IIV
CLS ~ VS (%)
- - 48.1 (36) 20.2 (1.8–32.1)
Residual variability
Proportional error
(%)
29.8 (21%) 29.1 (22.1–35.4) 29.8 (10) 28.5 (21.5–35.9)
R-ibuprofen parameters
CLR, ind = CLR,pop + ΘPNA,R *(PNAind-6 days)
CLR,pop (mL/h) - - 189 (24) 196 (128–286)
ΘPNA,R - - 32.3 (48) 28.5 (7.6–61.3)
VS,ind = VS,p
* (WTind/860 g)
ΘWT
VR,pop (mL) - - 303 (15) 280 (181–408)
Residual variability
Proportional error
(%)
- - 63.0 (23) 54.5 (29.0–91.0)
Additive error
(μg/mL)
- - 1.09 (14) 1.08 (0.78–1.44)
RSE: relative standard error; CI: confidence interval; CLS: clearance of S-ibuprofen; pop: population mean value of a parameter for an appropriate for gesta-
tional age individual with a PNA of 6 days, GA of 26 weeks and current weight of 860 g; PNAind: individual PNA in days; ΘPNA,S: exponent for influence of
PNA on CLS; ΘSGA: factor for influence of being small for gestational age on CLS, only applied for SGA preterm neonates; GA: gestational age in weeks;
GAind: individual GA; ΘGA: exponent of GA on CLS; VS: distribution volume of S-ibuprofen; WTind: individual current weight in g; ΘWT: exponent for influ-
ence of WT on VS and VR; IIV: interindividual variability; CLR: clearance of R-ibuprofen; ΘPNA,R: slope of influence of PNA on CLR; VR: volume of distribu-
tion of R-ibuprofen.
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however despite the effect of sex being slightly more significant than
WT regarding OFV in the backwards elimination, the effect of WT on
Vs was maintained in the model based on goodness-of-fit plots.
Parameter estimates of the S-ibuprofen model and the respective
bootstrap estimates are provided in Table 2.
3.3 | Population PK model of S- and R-ibuprofen
To the final model for S-ibuprofen, a model for R-ibuprofen was
added in which the R-ibuprofen data were described (Figure S3). R-
ibuprofen concentrations were best described by a 1-compartment
model with a combined residual error model (Table 2). IIV on CLR or
volume of distribution of R-ibuprofen (VR) could not be identified. The
influence of PNA on CLR was described by a linear function, estimat-
ing an increase of CLR of 32.3 mL/h per postnatal day. Despite the
lack of IIV on VR identified in the R-ibuprofen model, the effect of WT
was included on VR (P < .05). Estimation of 2 different exponents to
describe the effects of WT on Vs and VR separately was not found to
be statistically better compared to estimating 1 joint exponent (dOFV
0.002, P > .1); therefore, 1 exponent of 0.456 (RSE 36%) was esti-
mated for both volumes. The parameter estimates of the S-ibuprofen
model did not change substantially upon addition of R-ibuprofen
model and data (Table 2). Covariance of IIV on CLS and Vs was
included in the enantiomer model.
Figure 1 shows how CLS changes with PNA for AGA and SGA
preterm neonates with a GA of 25, 27 and 29 weeks and PNA ranging
from 2 to 18 days. In Figure 2, the maturation of both CLS and CLR
found in this study is compared to other studies performed in preterm
neonates, children and adults.
3.3.1 | Model evaluation
A stratified bootstrap on AGA and SGA preterm neonates was per-
formed because a strong effect of being SGA was observed in both
F IGURE 1 Effect of gestational age and postnatal age on
maturation of clearance of S-ibuprofen (CLS). Dots represent
individual estimates of CLS, with increasing colour intensity with GA.
Solid lines represent estimated functions for observed CLS, dashed
lines represent predicted functions for CLS
F IGURE 2 Maturation of clearance of total, S- or R-ibuprofen by the current study and other studies in preterm neonates (A) and preterm
neonates, children and adults (B). Studies presented for a postnatal age below 6 months (Hirt et al.8 and Gregoire et al.10) represent studies
performed in preterm neonates, studies in subjects older than 6 months did not distinguish on prematurity. Results of the studies of Rey et al.20
and Kelley et al.21 were expressed in mL/min/kg for which the respective clearances were calculated for the subjects with the minimal and
maximum age within the study. In the study of Anderson et al.22 clearance of total ibuprofen was predicted as function of postmenstrual age. The
dark blue line is drawn through calculated clearances for postnatal ages 1, 2, 3, 6, 12 months, and 2, 4, 6, 8, 10, 12 and 16 years
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the S-ibuprofen and the model of S- and R-ibuprofen. A goodness of
fit plot is presented in Figure 3. Results of the NPDE analysis stratified
on enantiomer are presented in Figure S4. Mean NPDE for S-
ibuprofen was 0.03481 (standard error = 0.062), variance 0.8224
(standard error = 0.08) and global adjusted P-value .0298. For R-
ibuprofen the mean NPDE was 0.07336 (standard error = 0.081), vari-
ance 1.371 (standard error = 0.13) and global adjusted P-value
.000589. PcVPCs of the continuous data vs time after dose, and of S-
ibuprofen vs weight and PMA are presented in Figures S5 and S6,
respectively.
3.4 | Evaluation and optimizing of dosing regimen
Concentration–time profiles of S- and R-ibuprofen in hypothetical
simulated preterm neonates dosed according to the label
(10-5-5 mg/kg) and as suggested by Hirt et al. are presented in
Figure 4.9 The highest exposure is observed in preterm neonates with
a GA of 27 weeks and a PNA of 1 day, illustrating the low CLS in both
SGA and AGA preterm neonates at PNA 1. In preterm neonates with
a GA of 27 weeks, a median AUC24 of S-ibuprofen (AUC24,S) of
467 mg h/L was observed when treatment according to the label was
initiated at postnatal day 1, of 426 mg h/L upon treatment initiation
at postnatal day 3 and of 318 mg h/L when treatment is initiated at
postnatal day 7. In SGA preterm neonates with the same age charac-
teristics these values were 414, 334 and 149 mg h/L, respectively.
Increasing the dose with PNA, as suggested by Hirt et al. prevents a
drop in AUC24,S after treatment initiation at PNA day 3 compared to
initiation at day 1 (620 and 464 mg h/L, respectively, for an AGA pre-
term neonate with a GA of 27 weeks). AUC24,S decreases, however,
when treatment is initiated at PNA day 7 (590 mg h/L; Figure 4).
The contribution of R-ibuprofen to the total exposure to ibupro-
fen decreases with PNA as result of the higher CLR than CLS and the
rapid increase of CLR with PNA. R-ibuprofen contributes 22% to the
F IGURE 3 Goodness of fit of the final enantiomer model. (A) Population predicted concentration of S- and R-ibuprofen (orange and blue
points respectively). (B) Individual predicted vs predicted concentrations of S- and R-ibuprofen. (C, D) Prediction of the fraction of observations to
be below the lower limit of quantification (BLOQ) for S- and R-ibuprofen (C and D, respectively). Solid black line represents the median fraction of
samples to be BLOQ based on 1000 simulations of the original dataset, black dashed lines represent the 95% confidence interval of the simulated
fraction BLOQ. The observed fraction BLOQ samples are represented with a solid red line
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total AUC24 when treatment is initiated at PNA 1 day. This contribu-
tion drops to 11 and 6% when initiation occurs on postnatal days
3 and 7, respectively, when GA is 27 weeks.
Heat maps in Figure 5 illustrate the variation in exposure to total
ibuprofen for a wide range in AGA preterm neonates. Consistent with
Figure 4, a lower AUC24 and AUC72 is observed when treatment
according to the label is initiated at higher PNAs. After dosing as
suggested by Hirt et al. i.e. increasing the dose with PNA, the lowest
median AUC24 is observed in preterm neonates with a GA of 24 weeks
and treatment initiation at PNA day 2 (410 mg h/L). The highest
median AUC24 was observed in a preterm with a GA of 30 weeks and
treatment initiation at PNA day 5.
Adjusting the dose only on postnatal days 3 and 5 appears to
cause a lower exposure in preterm neonate whose treatment initiates
at postnatal day 4 and PNA above 5 days. To obtain similar exposure
across this population, the dose needs to be increased every postnatal
day both at treatment initiation and during treatment. Starting with a
loading dose of 10 mg/kg for initiation at PNA 1 day, the loading dose
should be increased with 2 mg/kg for every postnatal day of treat-
ment initiation after day 1. The maintenance doses should be adjusted
accordingly, starting with a maintenance dose of 5 mg/kg once daily
24 hours after treatment is initiated at PNA day 1 and a dose increase
with 1 mg/kg for every postnatal day during the course. An overview
of the proposed loading dose and maintenance on each day of treat-
ment initiation is presented in Table 3.
Optimization of the dosing regimen results in less variation of
AUC24 and AUC72 between patients with different characteristics.
The range of AUC24 was 435–766 mg h/L using the optimized dosing
F IGURE 4 Concentration-time profiles of S- and R-ibuprofen in subjects dosed according to the label (10–5-5 mg/kg, top row) and as
advised by Hirt et al. (1000 simulations, bottom row).8 Treatment is initiated at postnatal day 1, 3 or 7 in appropriate for gestational age neonates
(columns 1–3) and small for gestational age neonates (columns 4–6). Subjects dosed as advised by Hirt et al.8 received a loading dose of 10 mg/kg
and 2 maintenance doses of 5 mg/kg every 24 hours when treatment was initiated at PNA 1, a loading dose of 14 mg/kg and 2 maintenance
doses every 24 hours of 7 mg/kg when treatment was initiated at PNA 3 days, and a loading dose of 18 mg/kg followed by 2 maintenance doses
of 9 mg/kg every 24 upon initiation at PNA 7 days. Both dosing advices are simulated in preterm neonates with gestational ages of 25, 27 and
29 weeks. Solid blue lines represent the median predicted concentration of S-ibuprofen of 1000 simulations, with a shaded area that represents
the 95% prediction interval. The 50% prediction interval is indicated with a dashed line. The red line presents the median predicted concentration
of R-ibuprofen of 1000 simulations
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regimen, vs 410–761 mg h/L when dosing as advised by Hirt et al.9
The ranges of AUC72 were 1406–2366 and 1038–2288 mg h/L after
dosing according to the optimized dosing regimen and Hirt et al.’s
advice, respectively.
4 | DISCUSSION
In this study, we were able to describe the PK of S-ibuprofen and to
estimate the exposure to the 2 ibuprofen enantiomers separately. In
contrast to previous studies, our cohort of patients has a relatively
wide range in PNA, reflecting contemporary practices. We found pro-
found effects of PNA, SGA and GA on CLS, which ask for dose adjust-
ments not only based on body weight, but also on age.
We developed a population PK model for the pharmacologically
active enantiomer S-ibuprofen in which a strong effect of PNA on CLS
was identified. A rapid increase of CLS with PNA is previously
F IGURE 5 Exposure to total ibuprofen 24 hours (top row) and 72 hours (bottom row) after the first ibuprofen dose of the first treatment
cycle, in preterm neonates with different combinations of gestational age and postnatal age at treatment initiation. The colour intensity of a
square represents the median AUC of total exposure of 1000 simulations. Left row: dosing following the label; a loading dose of 10 mg/kg
followed by 2 maintenance doses of 5 mg/kg every 24 hours. Middle row: dosing as advised by Hirt et al.8: a loading dose of 10 mg/kg and
2 maintenance doses of 5 mg/kg every 24 hours when treatment was initiated at postnatal age (PNA) 1, a loading dose of 14 mg/kg and
2 maintenance doses every 24 hours of 7 mg/kg when treatment was initiated at PNA 3 days, and a loading dose of 18 mg/kg followed by
2 maintenance doses of 9 mg/kg every 24 hours upon initiation at PNA 7 days. In the right column, the optimized dosing regimen was imputed:
10–5–5 mg/kg when initiated at PNA 1, 12–6–6 mg/kg when initiated at PNA 2, 14–7-7 mg/kg when initiated at PNA 3, 16–8-8 mg/kg when
initiated at PNA 4, 18–9-9 mg/kg when initiated at PNA 5, 20–10-10 mg/kg when initiated at PNA 6, 22–11-11 mg/kg when initiated at PNA
7 and 24–12-12 mg/kg when initiated at PNA 8. Combinations of initiation postnatal age and gestational age at the edge of both characteristics
not present in the original dataset were omitted (grey squares)
TABLE 3 Proposed dosing regimen with loading and
maintenance doses for each postnatal day of initiation from 1 to 8.
Administered doses above 20 mg/kg have not yet been reported and
are proposed based on simulation results only. Therefore, the doses
above 20 m/kg cannot be directly translated into the clinical practice
yet
Postnatal day of
treatment
initiation
Loading
dose
(mg/kg)
First
maintenance
dose (mg/kg)
Second
maintenance
dose (mg/kg)
1 10 5 6
2 12 6 7
3 14 7 8
4 16 8 9
5 18 9 10
6 20 10 11
7 22 11 12
>8 24 12 13
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described by Hirt et al., but might have been obscured by a narrower
range in PNA and no distinction between the enantiomers.9 While
CLS cannot directly be compared to clearance of total ibuprofen,
Figure 2 shows that the estimated maturation patterns are similar,
mutually reassuring estimated maturation within the available PNA
range. The maturation of CLS with PNA is expected to reach a plateau
at a higher PNA, but the PNA range in our study (0–18 days) was not
yet large enough to identify this. Because there is very limited evi-
dence for the treatment of PDA with ibuprofen after the first 2 weeks
of life, we do not regard the lack of identifying a plateau a limitation
of this study.23 However, caution is required when extrapolating
these results beyond the PNA range with available observations
(2–18 days).
The observed higher CLS in SGA vs AGA preterm neonates was
unexpected, since usually a decreased drug clearance is observed in
this subpopulation.24–28 This finding is substantiated by the lower
plasma levels of S-ibuprofen that can be observed in the raw data
(Figure S1A), despite the fact that the 2 groups received a similar dose
per kg body weight. Potential effects of the coadministration of flu-
conazole, known to decrease CLS, as well as differences in albumin
and bilirubin plasma levels were examined, but no differences
between SGA and AGA groups were identified.29 Even though the
number of SGA preterm neonates just reached the minimum of 10%
of the entire population (7 out of 67), only 14 plasma samples were
available taken relatively early during treatment (Table 1). We do not
consider these data sufficient to propose a dose increase for SGA pre-
term neonates, but we do see this as a strong signal that SGA preterm
neonates are different from their AGA peers in more than just birth
weight. A previously reported higher need for surgical ligation of PDA
in SGA preterm neonates after pharmacological treatment with indo-
methacin or ibuprofen might be explained by a higher clearance.30
More insight into the exposure–response relationship of ibuprofen,
and validation of the observed effect of being SGA is needed.
The opportunistic sampling approach used in this study allowed
us to study multiple drugs in parallel in a very fragile population, but
might not have resulted in the optimal data to study the PK of R-
ibuprofen.31–33 Despite this limited data we were able to confirm a
higher CLR compared to CLS, as also observed in other preterm neo-
nates and older populations (Figure 2).10,11,34–36 The limited data
available can also explain the lack of identification of chiral inversion
of R- to S-ibuprofen, as identified in piglets and well described in
adults.7,13 However, the varying fractions of R-ibuprofen dose to be
inverted identified by Gregoire et al. (17 and 61%) already suggested
difficulties with identifying this inversion in preterm neonates.
Because CLR is estimated to be substantially higher than CLS, poten-
tial inverted R-ibuprofen is expected to have little effect on exposure
to S-ibuprofen. For future studies, it appears to be sufficient to study
total ibuprofen, since the clinical impact of R-ibuprofen seems limited.
One other limitation of the present study was the lack of sufficient
data on enteral dosing of ibuprofen. Since a higher effectiveness is
observed after enteral administration of ibuprofen, identifying PK
parameters after gastro-enteral administration may be of relevance.5
Evaluation of population predicted- and individual predicted
concentration plots (Figure S4) on the log-scale reveals some under-
prediction of the lowest R-ibuprofen concentrations. The NPDE anal-
ysis (Figure S4) confirmed this under-prediction. However, despite the
suboptimal data- and predictions of R-ibuprofen, we believe that this
model adds valuable knowledge about enantiomer specific PK of ibu-
profen, particularly since minimal knowledge in this population is
available at the time of writing.
Heat maps and concentration–time profiles of currently used dos-
ing guidelines suggest a higher exposure in infants with a higher GA,
while the model predicts increasing CLS with GA. This appears to be
the result of linear scaling of doses with body weight, while Vs is not
predicted to increase linearly. Since steady-state is not yet reached
after 72 hours, the relatively lower Vs in preterm neonates with a
higher GA results in higher AUC24 and AUC72. Changing plasma albu-
min levels with GA might be underlying to the nonlinear increase of
VS and VR with GA.
37
The generally used 10–5-5 mg/kg dosing regimen results in large
variation in exposure, supporting the findings of Hirt et al.9 that a dose
increase is needed when treatment is initiated at a higher PNA. Hirt
et al.9 already suggested to increase the dose with 4 mg/kg at PNA
2.9 and 4.5 days, until a PNA of 7.5 days, which results in more similar
exposure in preterms starting at a PNA of 1 and 3 days compared to
dosing according to the label. However, this dosing regimen stops
increasing the dose after a PNA of 7.5 days. Because we had a wider
range of data in PNA (observations at 2–18 days), we were able to
detect that a further increase in dose would be necessary after
250 hours to maintain an equal exposure. Furthermore, the proposed
dosing regimen by Hirt et al.9 consists of a constant maintenance
dose, and Figure 4 shows that this will result in varying exposure
within the standard 3 days of treatment. A more frequent adjustment of
dose resulted in less varying exposure between different treatment
days and within 1 treatment regimen.
Based on current knowledge aiming for similar exposure seems to
be the first goal. Evidence for target exposure remains, however, lim-
ited and is not yet individualized. A described relationship between
GA and chance on spontaneous closure of the PDA suggests that sim-
ilar exposure might not suffice for achieving effective treatment of all
preterm neonates and underlines the need for further PK–
pharmacodynamic studies.12
Toxicity is certainly of interest as well, and knowledge on this
topic is also limited. The highest dosages of ibuprofen that have been
clinically evaluated in preterm neonates include a loading dose of
20 mg/kg and maintenance of 10 mg/kg, but a further increase might
be needed.5 The next step in optimizing the use of ibuprofen to treat
PDA is to perform a PK–pharmacodynamic analysis, with which indi-
vidual targets can be examined, and by including safety measures, a
maximum exposure can be determined.
5 | CONCLUSIONS
In this study, we described the enantiomer-specific PK and found that
S-ibuprofen clearance shows important maturation, especially with
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PNA, resulting in an up to 3-fold increase in CLS during a 3-day treat-
ment regimen. This rapid increase in clearance needs to be incorpo-
rated in dosing guidelines by adjusting the dose for every day after
birth to achieve equal ibuprofen exposure, also during a 3-day treat-
ment regimen. To obtain similar exposure in AGA preterm neonates,
the loading dose should be increased by 2 mg/kg for every postnatal
day of treatment initiation, starting with 10 mg/kg. A maintenance of
50% of the loading dose plus 1 mg/kg increase with every postnatal
day will result in minimal differences in exposure between different
PNAs. Studying enantiomer-specific PK of ibuprofen did not provide
us with new insights, and in future studies measuring total ibuprofen
suffices.
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